$QQQ

ETF Activity: QQQ Leads $4.37 Billion Outflow on Oct. 26

On Oct. 26, 2026, ETFs saw net outflows of $2.51 billion, with QQQ leading at -$4.37 billion, followed by IWD and IVV. Inflows were led by US01MC at $1.20 billion. Apple and Microsoft saw the largest reductions in holdings, while Taiwan Semiconductor saw the largest increase.

Original reporting
Published Oct 28, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ETF Activity: QQQ Leads $4.37 Billion Outflow on Oct. 26 — source image
Decision brief

The 30-second read

$QQQBearishLow
01

Why it matters

Large outflows from QQQ and IWD point to near-term caution toward Nasdaq-heavy and factor-exposed exposures. Stock-level trims in AAPL, MSFT, and AMZN suggest ETF-driven selling pressure, while adds in TSM and health care-linked names suggest selective buying.

02

Market read

Traders may use the flow imbalance as a short-term positioning signal for ETF-linked exposures into the next session.

03

What to watch

The article uses estimated holdings-change values, not confirmed trades, and does not attribute flows to specific catalysts beyond the flow magnitude itself.

Relevance 4/10Novelty 4/10Timing: for Tuesday positioning, based on Oct. 26 estimated ETF flow data

Background

The article summarizes estimated ETF flows for Oct. 26, highlighting net outflows across hundreds of funds and naming the largest ETF drags and stock-level trims/adds.

Company-level read

Ticker impact

$QQQBearishMedium confidence
Context

Article says QQQ had the largest single drag with an estimated -$4.37B outflow on Oct. 26, signaling risk-off ETF positioning.

Expected impact

Downward bias as the market weighs whether QQQ outflows persist into the next session.

Evidence & confidence

The piece provides a large, specific outflow figure for QQQ and explicitly flags watching persistence into Tuesday.

$IWDBearishMedium confidence
Context

Article reports IWD had the second-largest outflow at an estimated -$1.86B on Oct. 26, a direct read-through to US value/large-cap factor demand.

Expected impact

Likely pressure as investors reassess value-factor allocations based on ongoing outflow data.

Evidence & confidence

The article quantifies IWD’s outflow and frames it as something to monitor for persistence.

$IVVBearishLow confidence
Context

Article states IVV saw an estimated -$727.2M outflow on Oct. 26, indicating reduced appetite for broad S&P 500 exposure.

Expected impact

Slight downside bias if outflows continue, otherwise mean reversion is possible.

Evidence & confidence

The outflow is sizable but smaller than QQQ and IWD, and the article is a single-day flow snapshot.

$AAPLBearishLow confidence
Context

Article says ETFs trimmed AAPL by $389.1M in holdings value on Oct. 26, a direct signal of reduced passive/ETF demand.

Expected impact

Mild downside bias as traders track whether AAPL trimming persists in subsequent flow prints.

Evidence & confidence

The article provides a single-day estimated trim amount without confirming follow-through or causality beyond ETF flows.

$MSFTBearishLow confidence
Context

Article reports ETFs trimmed MSFT by $272.5M in holdings value on Oct. 26, indicating reduced ETF exposure to mega-cap tech.

Expected impact

Slight negative bias contingent on continued ETF outflows.

Evidence & confidence

This is an estimated holdings-change figure from ETF activity, not a company-specific catalyst.

$AMZNBearishLow confidence
Context

Article says ETFs cut AMZN by $225.8M in holdings value on Oct. 26, reflecting reduced passive demand for the stock.

Expected impact

Downward bias if ETF trims persist; otherwise limited follow-through.

Evidence & confidence

Single-day estimated trim with no additional confirmation of broader positioning changes.

$TSMBullishLow confidence
Context

Article notes ETFs added the most dollar value in TSM, adding $135.0M on Oct. 26, a positive flow signal for the semiconductor exposure.

Expected impact

Likely modest upward bias if inflows persist and risk appetite improves.

Evidence & confidence

The inflow is smaller than the largest outflows and is only one-day data.

$LLYBullishLow confidence
Context

Article reports ETFs added $62.0M in holdings value to LLY on Oct. 26, indicating selective buying in health care.

Expected impact

Mild positive bias if the health care inflow trend continues.

Evidence & confidence

The article provides a small estimated add and does not establish persistence beyond a watch item.

Market effects

Outflows concentrated in QQQ and IWD suggest pressure on growth and value-factor ETF demand, while health care (XLV mentioned) shows relative support.

Primarily US-focused passive flow signal, with potential spillover into US large-cap and factor ETFs.

Limited direct global linkage, but US ETF flow risk can influence global risk sentiment via US index exposure.

Counterpoint

Single-day ETF flow prints can mean rebalancing or hedging rather than a durable change in fundamentals, so follow-through may be limited.

Key entities

  • QQQ

    Largest single drag with an estimated -$4.37B outflow on Oct. 26.

  • IWD

    Second-largest outflow with an estimated -$1.86B on Oct. 26.

  • IVV

    Broad S&P 500 ETF with an estimated -$727.2M outflow on Oct. 26.

  • AAPL

    ETFs trimmed holdings value by $389.1M on Oct. 26.

  • MSFT

    ETFs trimmed holdings value by $272.5M on Oct. 26.

Related articles

$LLYMed

Lilly’s retatrutide shows greater efficacy than Ozempic in trial

Eli Lilly (NYSE:LLY) reported that retatrutide outperformed Ozempic in a Phase 3 trial for type 2 diabetes. Retatrutide reduced A1C levels by 2.2% vs. Ozempic's 1.8% and led to 44-47 lbs weight loss vs. Ozempic's 21 lbs. Both doses met primary and secondary endpoints. Common side effects included diarrhea and nausea. Retatrutide is not yet FDA-approved.

$LLYMedAI 8/10

Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial | Eli Lilly and Company

Eli Lilly's retatrutide showed greater A1C reduction (2.2%) and more than double the weight loss (44-47 lbs) compared to Ozempic (1.8%, 21 lbs) in a head-to-head trial with type 2 diabetes patients. Retatrutide also improved cardiovascular risk factors. Common side effects included gastrointestinal issues. Detailed results will be presented at a future medical meeting.

$LLYMedAI 8/10

Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss

Eli Lilly announced that retatrutide, a new drug in clinical trials, showed superior weight loss and blood sugar control compared to Ozempic. Patients on retatrutide lost 44-47 pounds vs. 21 pounds on Ozempic. Eli Lilly plans to seek FDA approval in 2027. Side effects were similar, with some differences. The company also warned about black-market sales of the unapproved drug.